Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 181 of the 182 references it cites were found in a registry or an index.

Phenotypic screening in cancer drug discovery — past, present and future

Moffat, John G., Rudolph, Joachim, Bailey, David · 2014 · Nature Reviews Drug Discovery

Abstract

There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches. Given that oncology is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncology drug discovery by analysing the origins of all new small-molecule cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clinical development. Although the majority of these drugs originated from target-based discovery, we identified a significant number whose discovery depended on phenotypic screening approaches. We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes. However, technical and biological advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncology.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd4366

Cites

181 of 181 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 182 references

Cited by

See all 523

Metadata

Authors
Moffat, J. G., Rudolph, J., & Bailey, D.
Affiliations
Genentech (US)
Corresponding author
Moffat, John G.
Venue
Nature Reviews Drug Discovery
Published
2014-07-18
Volume
13
Issue
8
Pages
588-602
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2123059506
Cited by
507
References
182
Citations by year
2026: 28 · 2025: 37 · 2024: 43 · 2023: 30 · 2022: 36 · 2021: 48 · 2020: 45 · 2019: 48 · 2018: 52 · 2017: 56 · 2016: 42 · 2015: 39 · 2014: 3
FWCI
3.85
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Funders
U.S. Food and Drug Administration
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
phenotypic screening, anticancer drug discovery, anticancer drug development, small molecule anticancer agents, FDA-approved anticancer drugs, target-based drug discovery, cytotoxicity, mitotic arrest
MeSH terms
Antineoplastic Agents, Drug Screening Assays, Antitumor, Forecasting, Humans, Neoplasms, Phenotype, History, 20th Century, History, 21st Century, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phenotypic screening in cancer drug discovery — past, present and future. https://app.cochat.ai/papers/10.1038/nrd4366
The paper
Moffat, J. G., Rudolph, J., & Bailey, D. (2014). Phenotypic screening in cancer drug discovery — past, present and future. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd4366

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.